"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA GRANTED ACCELERATED APPROVAL TO NIVOLUMAB (OPDIVO) FOR THE TREATMENT OF PATIENTS 12 YRS OR OLDER WITH MISMATCH REPAIR DEFICIENT AND MICROSATELLITE INSTABILITY HIGH METASTATIC COLORECTAL CANCER

FDA GRANTED ACCELERATED APPROVAL TO NIVOLUMAB (OPDIVO) FOR THE TREATMENT OF PATIENTS 12 YRS OR OLDER WITH MISMATCH REPAIR DEFICIENT AND MICROSATELLITE INSTABILITY HIGH METASTATIC COLORECTAL CANCER

07 Aug 2017 9:30 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients 12 years and older with mismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) metastatic colorectal cancer that has progressed following treatmetn with fluoropyrimidine, oxaliplatin, and irinotecan. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software